4//SEC Filing
ELMS STEVE 4
Accession 0000950142-17-002107
CIK 0001581720other
Filed
Nov 26, 7:00 PM ET
Accepted
Nov 27, 7:29 PM ET
Size
29.9 KB
Accession
0000950142-17-002107
Insider Transaction Report
Form 4
Aisling Capital Partners III LP
10% Owner
Transactions
- Sale
Common Stock
2017-11-22$75.00/sh−500,000$37,500,000→ 3,688,920 total
AISLING CAPITAL III LP
10% Owner
Transactions
- Sale
Common Stock
2017-11-22$75.00/sh−500,000$37,500,000→ 3,688,920 total
Aisling Capital Partners III LLC
10% Owner
Transactions
- Sale
Common Stock
2017-11-22$75.00/sh−500,000$37,500,000→ 3,688,920 total
ELMS STEVE
Director10% Owner
Transactions
- Sale
Common Stock
2017-11-22$75.00/sh−500,000$37,500,000→ 3,688,920 total
SCHIFF ANDREW N
10% Owner
Transactions
- Sale
Common Stock
2017-11-22$75.00/sh−500,000$37,500,000→ 3,688,920 total
Purcell Dennis J
10% Owner
Transactions
- Sale
Common Stock
2017-11-22$75.00/sh−500,000$37,500,000→ 3,688,920 total
Footnotes (1)
- [F1]The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.
Issuer
Loxo Oncology, Inc.
CIK 0001581720
Entity typeother
Related Parties
1- filerCIK 0001250195
Filing Metadata
- Form type
- 4
- Filed
- Nov 26, 7:00 PM ET
- Accepted
- Nov 27, 7:29 PM ET
- Size
- 29.9 KB